Moderna and Canada Announce Collaboration to Bring mRNA Manufacturing to Canada

Manufacturing facility to provide access to domestically manufactured vaccines against respiratory viruses

Collaboration will support Canada with direct access to rapid pandemic response capabilities

First instance of sustainable national business model that Company expects to apply to other geographies

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced a Memorandum of Understanding (MoU) with the government of Canada to build a state-of-the-art messenger RNA (mRNA) vaccine manufacturing facility in Canada including access to Moderna’s mRNA development engine. The goals of this MoU are to build the foundation to support Canada with direct access to rapid pandemic response capabilities and to provide access to Moderna’s vaccines in development for respiratory viruses.

“I would like to thank the Government of Canada for the partnership they have built with us and for their faith in our data, science and early confidence in our mRNA platform in addressing the COVID-19 pandemic. We recently announced data from the final analysis of the Phase 3 COVE study demonstrating that vaccination with the Moderna COVID-19 vaccine showed 93% efficacy, with this efficacy remaining durable six months after administration of the second dose,” said Stéphane Bancel, Chief Executive Officer of Moderna. “As a company, we are committed to global public health. While we are still responding to this pandemic, we also want to ensure we and society learn from it. As Moderna expands internationally, we are delighted to bring mRNA manufacturing to Canada. We believe that this innovative business model will have global impact and implications.”

Moderna is committed to working with governments, health care professionals and other key stakeholders to meet the challenges of the COVID-19 pandemic and future pathogens. Moderna expects to invest in a state-of-the-art manufacturing facility with the collaboration of the Canadian government. The collaboration aims to provide Canadians with access to a domestically manufactured portfolio of mRNA vaccines against respiratory viruses, including COVID-19, seasonal influenza, respiratory syncytial virus (RSV) and potential other vaccines, pending licensure. The facility is intended to also be activated on an urgent basis to support Canada with direct access to rapid pandemic response capabilities. The Company is in discussion with other governments about potential collaborations built on a similar model.

“We are excited to expand our presence and continue our long-term collaboration with Canada,” said Patricia Gauthier, Moderna’s Canadian General Manager. “With our industry-leading mRNA technology platform and rapid drug development capabilities, we look forward to being an active participant in Canada’s robust life sciences ecosystem.”

The MoU was announced today by the Hon. François-Philippe Champagne, Minister of Innovation, Science and Industry of Canada, and Stéphane Bancel, Moderna’s Chief Executive Officer in Montreal, Canada.

About Moderna

In 10 years since its inception, Moderna has transformed from a science research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across six modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and at unprecedented speed. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna’s capabilities have come together to allow the authorized use of one of the earliest and most-effective vaccines against the COVID-19 pandemic.

Moderna’s mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Today, 23 development programs are underway across these therapeutic areas, with 15 programs having entered the clinic. Moderna has been named a top biopharmaceutical employer by Science for the past six years. To learn more, visit www.modernatx.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding the Company’s collaboration with the Canadian government to develop mRNA manufacturing facilities in Canada; the types of medicines to be manufactured at the facility and pandemic response capabilities; the efficacy of the Moderna COVID-19 Vaccine over time; and potential collaborations with other governments to develop mRNA manufacturing capabilities globally. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include those other risks and uncertainties described under the heading “Risk Factors” in Moderna’s most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date hereof.

Contacts

Moderna Contacts

Canadian Media:
Paul Monlezun

613-222-7184

paul.monlezun@publicaffairsadvisors.com

Media:
Colleen Hussey

Director, Corporate Communications

617-335-1374

Colleen.Hussey@modernatx.com

Investors:
Lavina Talukdar

Senior Vice President & Head of Investor Relations

617-209-5834

Lavina.Talukdar@modernatx.com